48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis
Table 3
Difference (95% CrI) between direct clinical trial data and indirect model estimates.